




[SEQ ID NO: 2879] or a salt thereof.




[SEQ ID NO: 2879]


In certain embodiments, a compound comprises or consists of the sodium salt of compound 951799 having the following chemical structure:



[SEQ ID NO: 2879]



[SEQ ID NO: 2879] or a salt thereof.



[SEQ ID NO: 2879]

CLAIMS

1. A compound comprising a modified oligonucleotide consisting of 14 to 30 linked nucleosides and having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 2123, 2189, 2160, 3056, 2453, or 2232.

2. The compound according to claim **1**, wherein the modified oligonucleotide comprises:

a gap segment consisting of 8-12 linked 2'-deoxynucleosides;

a 5' wing segment consisting of 1-7 linked nucleosides; and

a 3' wing segment consisting of 1-7 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein the terminal nucleoside of each wing segment comprises a modified sugar.

3. The compound according to claim **2**, wherein the gap segment consists of 10 linked 2'-deoxynucleosides.

4. The compound according to claim **2** or **3**, wherein the 5' wing segment consists of 3 linked nucleosides.

5. The compound according to any one of claims **2** to **4**, wherein the 3' wing segment consists of 3 linked nucleosides.

6. The compound according to any one of claims **1** to **5**, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

7. The compound according to claim **6**, wherein the at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.

8. The compound according to any one of claims **1** to **7**, wherein the modified oligonucleotide comprises at least one bicyclic sugar.

9. The compound according to claim **8**, wherein the at least one bicyclic sugar is selected from the group consisting of LNA, ENA, and cEt.

10. The compound according to any one of claims **1** to **9**, wherein the modified oligonucleotide comprises at least one 5 -methylcytosine.

11. The compound according to any one of claims **1** to **10**, wherein the modified oligonucleotide is single-stranded.

12. The compound according to any one of claims **1** to **11**, wherein the compound is a double-stranded compound.

13. The compound according to any one of claims **1** to **12**, wherein the modified oligonucleotide consists of 16 to 20 linked nucleosides.

14. The compound according to any one of claims **1** to **13** comprising a conjugate group.


15. The compound according to claim **14,** wherein the compound consists of the modified oligonucleotide and the conjugate group.

16. A modified oligonucleotide according to the following formula: Gks Tks Tks Tds Ads Tds Tds Ads Tds Ads Gds Gds Gds mCks Tks Tk; wherein,

A = an adenine,
mC = a 5-methylcytosine
G = a guanine,
T = a thymine,
k = a cEt sugar moiety,
d = a 2'-deoxyribosyl sugar moiety, and
s = a phosphorothioate internucleoside linkage.

17. A compound comprising the modified oligonucleotide of claim **16**, wherein the modified oligonucleotide is covalently linked to a conjugate group.


18. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2879), or a salt thereof.

19. The modified oligonucleotide according to claim **18**, which is the sodium salt or the potassium salt.

20. A modified oligonucleotide, wherein the anion form of the modified oligonucleotide has the following chemical structure:




(SEQ ID NO : 2879).

21. The modified oligonucleotide according to claim **20**, wherein the modified oligonucleotide is a salt.

22. The modified oligonucleotide according to claim **21**, wherein the cation of the salt is sodium or potassium.

23. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2879).

24. A compound consisting of a pharmaceutically acceptable salt form of any one of the compounds according to any one of claims **1** to **15** and **17**.

25. The compound according to claim **24**, wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

26. A chirally enriched population of the compounds according to any one of claims **1** to **15, 17** or **24**, or of the modified oligonucleotides according to any one of claims **16,** and **18** to **23**, wherein the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having a particular stereochemical configuration.

27. A pharmaceutical composition comprising

the compound according to any one of claims **1** to **15, 17** or **24**,

the modified oligonucleotide according to any one of claims **16** or **18** to **23,** or

the population according to claim **26,**

and at least one pharmaceutically acceptable diluent or carrier.

28. The pharmaceutical composition according to claim **27**, wherein the pharmaceutically acceptable diluent is phosphate buffered saline.

29. The pharmaceutical composition according to claim **27** or **28,** wherein the pharmaceutical composition consists essentially of the modified oligonucleotide(s) and phosphate buffered saline.

30. Use of the compound according to any one of claims **1** to **15, 17** or **24**, the modified oligonucleotide according to any one of claims **16** or **18** to **23**, the population according to claim **26** or the pharmaceutical composition according to any one of claim **27** to **29** in the preparation of a medicament for treating, preventing, or ameliorating a disease associated with DNM2 in an individual.

31. The use according to claim **30**, wherein the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, Charcot-Marie Tooth disease, X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy.

32. The use according to claim **30**, wherein the disease is associated with a mutation in at least one gene selected from among MTM1, BIN1, and DNM2.

33. Use of the compound according to any one of claims **1** to **15, 17** or **24**, the modified oligonucleotide according to any one of claims **16** or **18** to **23**, the population according to claim **26** or the pharmaceutical composition according to any one of claims **27** to **29** in the preparation of a medicament for treating, preventing or ameliorating a disease associated with DNM2 by reducing DNM2 RNA in a cell.